Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
electroCore (ECOR) Upgraded to Buy: Here's What You Should Know
electroCore (ECOR) Q3 2026 Earnings Call Transcript
electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore Inc (ECOR) (Q3 2026) Earnings Call Highlights: Record Sales, Narrowing Losses, and ...
electroCore Q3 Earnings Call Highlights
electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue Estimates
electroCore Announces Third Quarter 2026 Financial Results
CORRECTION: electroCore Widens FY2026 Sales Guidance from $41.600M to $39.000M-$42.000M vs $41.915M Est
electroCore Q3 2026 Earnings Call Transcript
electroCore Sees FY 2027 revenue guidance of 30% to 40% YoY
electroCore Q3 EPS $(0.13) Beats $(0.27) Estimate, Sales $9.690M Miss $10.928M Estimate
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
electroCore Targets 2027 EBITDA Profit as VA, Quell and CIPN Opportunities Expand
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy
fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning
electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
electroCore Has A Line Of Sight At Cash Breakeven
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.